Cost of Revenue: Key Insights for BioMarin Pharmaceutical Inc. and Celldex Therapeutics, Inc.

Biotech Cost Trends: BioMarin vs. Celldex

__timestampBioMarin Pharmaceutical Inc.Celldex Therapeutics, Inc.
Wednesday, January 1, 2014129764000101881000
Thursday, January 1, 20151520080004011000
Friday, January 1, 2016209620000102026000
Sunday, January 1, 201724178600096171000
Monday, January 1, 201831526400066449000
Tuesday, January 1, 201935946600042672000
Wednesday, January 1, 202052427200042534000
Friday, January 1, 20214705150003068000
Saturday, January 1, 20224836690001400000
Sunday, January 1, 20235770650003008000
Monday, January 1, 2024580235000
Loading chart...

Unleashing insights

Cost of Revenue Trends: BioMarin vs. Celldex

In the competitive landscape of biotechnology, understanding cost structures is crucial. BioMarin Pharmaceutical Inc. and Celldex Therapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. BioMarin's cost of revenue has surged by approximately 345%, reflecting its expanding operations and increased production capabilities. In contrast, Celldex's costs have fluctuated, peaking in 2016 and then declining by about 97% by 2023, indicating strategic shifts or operational scaling back.

Key Insights

  • BioMarin's Growth: From 2014 to 2023, BioMarin's cost of revenue increased steadily, highlighting its robust growth and market expansion.
  • Celldex's Variability: Celldex experienced a significant drop in costs post-2016, suggesting a potential pivot in business strategy or product focus.

These insights provide a window into the strategic decisions and market dynamics influencing these biotech giants over the past decade.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025